233 related articles for article (PubMed ID: 26220995)
21. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
22. Protection against High-Fat-Diet-Induced Obesity in MDM2
Liu S; Kim TH; Franklin DA; Zhang Y
Cell Rep; 2017 Jan; 18(4):1005-1018. PubMed ID: 28122227
[TBL] [Abstract][Full Text] [Related]
23. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function.
Chen D; Zhang Z; Li M; Wang W; Li Y; Rayburn ER; Hill DL; Wang H; Zhang R
Oncogene; 2007 Aug; 26(35):5029-37. PubMed ID: 17310983
[TBL] [Abstract][Full Text] [Related]
24. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
25. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
26. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction.
Macias E; Jin A; Deisenroth C; Bhat K; Mao H; Lindström MS; Zhang Y
Cancer Cell; 2010 Sep; 18(3):231-43. PubMed ID: 20832751
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability.
Dolezelova P; Cetkovska K; Vousden KH; Uldrijan S
FEBS Lett; 2012 Jul; 586(16):2225-31. PubMed ID: 22659184
[TBL] [Abstract][Full Text] [Related]
28. Loss of RPS27a expression regulates the cell cycle, apoptosis, and proliferation via the RPL11-MDM2-p53 pathway in lung adenocarcinoma cells.
Li H; Zhang H; Huang G; Bing Z; Xu D; Liu J; Luo H; An X
J Exp Clin Cancer Res; 2022 Jan; 41(1):33. PubMed ID: 35073964
[TBL] [Abstract][Full Text] [Related]
29. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
30. Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis.
Marechal V; Elenbaas B; Taneyhill L; Piette J; Mechali M; Nicolas JC; Levine AJ; Moreau J
Oncogene; 1997 Mar; 14(12):1427-33. PubMed ID: 9136986
[TBL] [Abstract][Full Text] [Related]
31. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
32. Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain.
Yadavilli S; Mayo LD; Higgins M; Lain S; Hegde V; Deutsch WA
DNA Repair (Amst); 2009 Oct; 8(10):1215-24. PubMed ID: 19656744
[TBL] [Abstract][Full Text] [Related]
33. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
Uldrijan S; Pannekoek WJ; Vousden KH
EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
[TBL] [Abstract][Full Text] [Related]
34. The RP-Mdm2-p53 pathway and tumorigenesis.
Miliani de Marval PL; Zhang Y
Oncotarget; 2011 Mar; 2(3):234-8. PubMed ID: 21406728
[TBL] [Abstract][Full Text] [Related]
35. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
[TBL] [Abstract][Full Text] [Related]
36. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
37. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11.
Sasaki M; Kawahara K; Nishio M; Mimori K; Kogo R; Hamada K; Itoh B; Wang J; Komatsu Y; Yang YR; Hikasa H; Horie Y; Yamashita T; Kamijo T; Zhang Y; Zhu Y; Prives C; Nakano T; Mak TW; Sasaki T; Maehama T; Mori M; Suzuki A
Nat Med; 2011 Jul; 17(8):944-51. PubMed ID: 21804542
[TBL] [Abstract][Full Text] [Related]
38. Physical and functional interaction between ribosomal protein L11 and the tumor suppressor ARF.
Dai MS; Challagundla KB; Sun XX; Palam LR; Zeng SX; Wek RC; Lu H
J Biol Chem; 2012 May; 287(21):17120-17129. PubMed ID: 22467867
[TBL] [Abstract][Full Text] [Related]
39. The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.
Kannemeier C; Liao R; Sun P
Mol Biol Cell; 2007 Jun; 18(6):2367-77. PubMed ID: 17429071
[TBL] [Abstract][Full Text] [Related]
40. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
